STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib

Table 1 Association between clinicopathological features, STOML2 expression and survival

Factors	OS				TTR
	Univariate P value	Multivariate			Univariate P value	Multivariate
	Univariate P value	HR	95% CI	P value	Univariate P value	HR	95% CI	P value
Hepatitis B e antigen: positive versus negative	0.038	1.547	1.033–2.318	0.034	0.013	1.709	1.169–2.498	0.006
AFP (≤ 400 versus > 400 ng/ml)	0.024			NS	0.005			NS
Tumor differentiation: low versus high	0.027	1.920	1.192–3.095	0.007	0.235			NA
Vascular invasión(yes vs. no)	< 0.001			NS	0.001			NS
Tumor size (≤ 5 vs. > 5 cm)	< 0.001	2.963	1.864–4.710	< 0.001	< 0.001	2.108	1.392–3.193	< 0.001
Tumor number (single versus. multiple)	0.004			NS	0.008			NS
UICC TNM stage (I vs. II vs. IIIA)	< 0.001	1.703	1.274–2.275	< 0.001	< 0.001	1.548	1.186–2.022	0.001
STOML2 (low vs. high)	0.001	1.596	1.057–2.410	0.026	0.003	1.638	1.120–2.395	0.011

OS overall survival, TTR time to recurrence, CI, confidence interval, HR hazard ratio, NA not adopted, NS not significant, AFP α-fetoprotein, UICC International Union Against Cancer, TNM tumor-node-metastasis, STOML2 Stomatin-like protein 2

ISSN: 1756-8722